Related Experiment Video
Updated: May 20, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Alexandra Bartolomucci1,2, Monyse Nobrega1,2, Tadhg Ferrier1,2
1Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Abstract:
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its increasing integration into clinical practice. Carrying tumor specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a focus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
07:47Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
Published on: December 25, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy